ASCENTAGE PHARMA
Ascentage Pharma develops novel small-molecule therapies for cancer, hepatitis B, and age-related diseases. They have developed a pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions and are next-generation tyrosine kinase inhibitors.
ASCENTAGE PHARMA
Industry:
Biopharma Biotechnology Medical Pharmaceutical
Founded:
2009-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Website Url:
http://www.ascentagepharma.com
Total Employee:
101+
Status:
Active
Contact:
+86 512 855 57777
Total Funding:
312.49 M USD
Technology used in webpage:
Domain Not Resolving SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Alibaba AliDNS
Similar Organizations
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
SyneuRx International Taiwan Corp.
SyneuRx is a bio-medical company that develops drugs for the treatment of central nervous system-related disorders.
T Cell Nouveau
T Cell Nouveau is a clinical-stage biopharmaceutical company that focuses on curing solid tumors with hybrid CAR-T cell therapy.
Tripod Preclinical Research Laboratories
Tripod provides preclinical research services for global pharma companies, R&D enterprises and institutes and medical device developers.
Current Employees Featured
Dajun Yang President ,Chairman of the Board, Executive Director & Chief Executive Officer @ Ascentage Pharma
President ,Chairman of the Board, Executive Director & Chief Executive Officer
Jeff Kmetz Chief Business Officer @ Ascentage Pharma
Chief Business Officer
2019-02-01
Ming Guo Co-Founder & COO @ Ascentage Pharma
Co-Founder & COO
2009-01-01
Yiqing Chen Chief Financial Officer (CFO) @ Ascentage Pharma
Chief Financial Officer (CFO)
2021-11-01
Yifan Zhai Chief Medical Officer @ Ascentage Pharma
Chief Medical Officer
2012-07-01
Founder
Stock Details
Investors List
Takeda
Takeda investment in Post-IPO Equity - Ascentage Pharma
CTS Capital
CTS Capital investment in Series C - Ascentage Pharma
Teng Yue Partners
Teng Yue Partners investment in Series C - Ascentage Pharma
HDY International Investment
HDY International Investment investment in Series C - Ascentage Pharma
Oriza Seed Capital (Oriza Yuandian)
Oriza Seed Capital (Oriza Yuandian) investment in Series C - Ascentage Pharma
YuanMing Capital
YuanMing Capital investment in Series C - Ascentage Pharma
ArrowMark Partners
ArrowMark Partners investment in Series C - Ascentage Pharma
CCB International
CCB International investment in Series C - Ascentage Pharma
SDIC Fund Management
SDIC Fund Management investment in Series B - Ascentage Pharma
Oriza Holdings
Oriza Holdings investment in Series B - Ascentage Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-31 | Heluoxintu | Ascentage Pharma investment in Angel Round - Heluoxintu | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-29 | Ascentage Pharma Appoints Mr. Yiqing Chen as Chief Financial Officer |
Official Site Inspections
http://www.ascentagepharma.com
- Host name: catl.com
- IP address: 203.107.45.167
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Ascentage Pharma"
About Us - Ascentage Pharma
We are a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies. Our lead …See details»
Ascentage Pharma - Crunchbase Company Profile
Organization. Ascentage Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email bd@ascentagepharma.com; Phone Number +86 512 855 …See details»
A Leader in the Discovery and Development of First
Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs. For more than two …See details»
Ascentage Pharma Group Company Profile | Management and
Www.ascentagepharma.com . Ascentage Pharma Group Profile and History. Ascentage Pharma is a globally-focused, clinical-stage biotechnology company engaged in developing novel …See details»
Ascentage Pharma Management Team | Org Chart - RocketReach
Ascentagepharma.com; View Similar People. Related Companies Adagene. 74 $10.2m PharmaBlock Group. 169 $187.1m Reistone Biopharma. 56 $26.3m Genor BioPharma Co., …See details»
Ascentage Pharma - LinkedIn
Ascentage Pharma | 7,069 followers on LinkedIn. Ascentage Pharma is a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and …See details»
Ascentage Pharma: Contact Details and Business Profile
Ascentage Pharma is a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and senesce diseases.See details»
Ascentage Pharma - LinkedIn
Ascentage Pharma | 5,855 followers on LinkedIn. Ascentage Pharma is a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and …See details»
Ascentage Pharma Group International
IR Contact: IR@ascentagepharma.com Address: Level 1/2, Building 5, No. 338 Jialilue Road, Pudong New District, Shanghai Phone Number: 86–21–61951088. ... “CMO” a contract …See details»
Ascentage Pharma Group
Integrated organization in China, United States, Europe and Australia Dedicated team Global development Strongpipeline. 3 Major Achievements in 2021 nThe first and the only approved …See details»
Ascentage Pharma Company Overview, Contact Details
Doe@ascentagepharma.com: 3%. See more formats. Frequently Asked Questions Where is Ascentage Pharma 's headquarters located? Ascentage Pharma 's main headquarters is …See details»
Ascentage Pharma - Craft
Oct 25, 2024 Ascentage Pharma has 5 employees across 6 locations and ¥221.98 m in annual revenue in FY 2023. See insights on Ascentage Pharma including office locations, …See details»
Ascentage Pharma - Company Profile - Tracxn
Nov 5, 2024 Email ID: *****@ascentagepharma.com; Key Metrics. Total Funding. $238M in 3 rounds. Latest Funding Round. Series C, Jul 17, 2018, $150M. Investors. Oriza Ventures & 14 …See details»
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2020
Email: IR@ascentagepharma.com Address: Level 1/2, Building 5, No. 338 Jialilue Road, Pudong New District, Shanghai Phone number: 86-21-61951088. 2020 Report 2020 Environmental, …See details»
Ascentage Pharma Group - Overview, News & Similar companies
Apr 24, 2024 AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting ROCKVILLE, Md. and SUZHOU, …See details»
Ascentage Pharma Group Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Ascentage Pharma Group Inc. of Rockville, MD. Get the latest business insights from Dun & Bradstreet.See details»
Ascentage Pharma Group
2020 Key Achievements Clinical Proof of Concept (POC) of APG-2575 established in r/r CLL 9 ODD and 1 FTD (HQP1351 in TKI resistant CML) 2 global clinical collaborations with …See details»
Press Releases - Ascentage Pharma
Dec 26, 2024 ROCKVILLE, MD, the United States, and SUZHOU, China, December 10, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in …See details»
Ascentage Pharma Group
Major Achievements Over Last 12 Months 5 Clinical Proof of Concept (POC) of APG-2575 established inr/r CLL 1 NDA with “Priority Review” and“Breakthrough Therapy” for HQP1351 …See details»
Ascentage Pharma Group
PROPRIETARY AND CONFIDENTIAL 2020 H1 Key Achievements Started 4 new Phase Ib/II studies of APG-2575 both in China and U.S. APG-115, APG-1387 and APG-1252 entered into …See details»